Shortage of Remifentanil Hydrochloride Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Remifentanil Hydrochloride Injection, with some presentations available from certain manufacturers and others unavailable, as last updated on April 3, 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Remifentanil Hydrochloride Injection.
What's in Shortage
The drug in shortage is Remifentanil Hydrochloride Injection, with brand names ULTIVA and REMIFENTANIL HYDROCHLORIDE. It is an injection dosage form in the therapeutic category of Analgesia/Addiction. The shortage status is current, first posted on June 28, 2022, and last updated on April 3, 2026.
Which Manufacturers Are Affected
- Mylan Institutional, a Viatris Company: This manufacturer has the following presentations available: Ultiva Injection 2 mg (NDC 72078-035-02), Ultiva Injection 1 mg/1 mL (NDC 72078-034-01), and Ultiva Injection 5 mg (NDC 72078-036-05). Contact them at 800-796-9526.
- Fresenius Kabi USA, LLC: This manufacturer has the following: Remifentanil Hydrochloride Injection 1 mg/1 mL (NDC 63323-725-10) available, with a note to check wholesalers for inventory; Remifentanil Hydrochloride Injection 1 mg/1 mL (NDC 63323-723-03) unavailable, with next release in April 2026 and a note to check wholesalers; and Remifentanil Hydrochloride Injection 1 mg/1 mL (NDC 63323-724-05) available, with a note to check wholesalers for inventory. Contact them at 888-386-1300.
Why There's a Shortage
No specific reason was given for the shortage.
What Patients Should Do
Patients who rely on this medication should talk to their pharmacist about availability and options. They can also contact the relevant manufacturer for more information. Remember, patients should consult their healthcare provider for any guidance, as this article does not provide medical advice.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,598 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.